Although billions of suppositories are sold around the world each year, there is no standard of care for their administration. Sephure will make its debut at Digestive Disease Week in Chicago May 3-6th.

Necessity was the mother of invention for Ensign who was diagnosed with inflammatory bowel disease more than 20 years ago and lived with infrequent flares. Each dose took 30-45 minutes lying in the prone position, inserting the suppository with her finger and resisting the urgency to release the medication.

Upon standing, she needed to wear protective undergarments because the medicine leaked outside the body. Within a few months the regimen became too burdensome for Ensign and she abandoned her treatment.

Sephure has CE marking and is FDA cleared for marketing and distribution in the US.

Cristcot founder and CEO Jennifer Davagian Ensign said that at first it was difficult talking about something so private in a public forum.

"By telling my story I hope to create a new standard of care and in the process, improve the quality of life of others who struggle with the difficulties of suppository treatment," Ensign added.